Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioThrax Dosing Regimens for Anthrax Post-Exposure Prophylaxis
NCT01641991Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2012
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anthrax vaccine adsorbed in anthrax (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants With a Four-fold or Greater Increase From Baseline in Toxin Neutralization Antibody Assay (TNA) 50 Percent Neutralization Factor (NF50) Antibody Titer. Started Jul 2012; status: completed.
02
Drugs
anthrax vaccine adsorbed
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT01641991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01641991.